AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03125668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: After hospital discharge they receive a telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months).~During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment.
Study NCT03125668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to face counseling
Description: They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
Study NCT01591278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Comparison of two different pulp dressing agents
Study NCT01585415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will administered orally twice a day at a dose of 960 mg from day -21 (+/- 7 days)until disease progression or patients are taken off protocol.
Study NCT01585415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Young TIL will be administered intravenously on day 0(1x10e9 to 2x10e11) in the Patient Care Unit over 20-30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping.
Study NCT01585415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study NCT01585415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
Study NCT01585415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 720,000 IU/kg IV (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)
Study NCT02095626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-301
Description: orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days
Study NCT02095626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days
Study NCT01733186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CARTISTEM®
Study NCT00962949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II infusion for 1 hour
Study NCT00864487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: HKI-272
Study NCT01150513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC-T
Description: four cycles of EC (epirubicin: 90 mg/m2; cyclophosphamide :600 mg/m2, day 1) followed by four cycles of T (docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
Study NCT01150513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP
Description: six cycles of TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
Study NCT02127229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopist informed of cost per procedure
Description: Following each procedure, endoscopists will get a cost report regarding the amount spent on disposable accessories.
Study NCT01073059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid and Ertapenem
Study NCT00568776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: ELND005 matched placebo capsules for oral administration, bid for 78 weeks
Study NCT00568776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELND005
Description: ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
Study NCT00568776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELND005
Description: ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
Study NCT00568776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELND005
Description: ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
Study NCT00246194 — intervention group
Intervention type: DRUG
Intervention: risperidone (RISPERDAL CONSTA)
Description: Long-acting injectable of risperidone given as per the prescription from the prescribing physician.
Study NCT03035825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral moisturizing jelly
Description: Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth
Study NCT02638961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IMT
Description: Patients allocated to IMT arm will receive standard medical treatment and will be instructed to train at home twice daily, for 20 minutes each session, and during 12 weeks using a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them will be instructed by a respiratory therapist and educated to maintain a diaphragmatic breathing during the training period. The subjects start breathing at a resistance equal to 25-30% of their maximal inspiratory pressure (MIP) for 1 week. The respiratory therapist examines the patients at weekly intervals by checking the diary card and measuring their MIP each time. The resistance is modified each session according to their 25-30% of their MIP measured.
Study NCT02638961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FES
Description: Patients allocated to FES arm will receive standard medical treatment and will be trained in a FES program of both legs by a physiotherapist for 45 minutes a day, 2 days per week for a total of 12 weeks. Eight adhesive electrodes are positioned on the skin over the quadriceps and gastrocnemius muscles of both legs. The stimulator is configured to deliver a direct electrical current at 25 Hz for 5 seconds followed by a 5-second rest. The intensity of the stimulation is adjusted to achieve a visible muscle contraction without discomfort.
Study NCT02638961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Patients allocated to this arm will not receive any physical therapy, only standard medical treatment. They will be checked weekly by a physiotherapist who measures their maximal inspiratory mouth pressure each time.
Study NCT00415142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saredutant (SR48968)
Description: oral administration (capsules)
Study NCT03035825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artificial saliva
Description: A non-edible oral lubricating gel for dry mouth patients
Study NCT01598363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral, Day 1 and Day 10
Study NCT01598363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral, Day 1 and Day 10
Study NCT00014495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00014495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00014495 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: bismuth Bi213 monoclonal antibody M195
Study NCT00616837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Description: Outpatient consultation by help of telemedicine (video conference)
Study NCT00616837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care in orthopaedic outpatient clinic
Description: Standard care in orthopedic outpatient clinic (usual care)
Study NCT01580852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dead Sea water
Description: Subjects will immerse in mineral (dead sea) waters for twenty minutes twice daily for a period of 10 days
Study NCT01580852 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pool water
Description: Subjects will immerse in sweet(pool)waters for twenty minutes twice daily for a period of 10 days
Study NCT02109627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: 5-20 mg/kg; intravenous; Days 0, 14, 28, and 42. Number of cycles: until progression or unacceptable toxicity develops.
Study NCT03125668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to face counseling
Description: They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
Study NCT03448549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: adjuvant chemotherapy
Study NCT03448549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: adjuvant chemotherapy
Study NCT03448549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur，gimeracil and oteracil potassium
Description: adjuvant chemotherapy
Study NCT03448549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeloda
Description: adjuvant chemotherapy
Study NCT01617421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation \[9\]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
Study NCT00775918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline monohydrate 100mg tablets
Description: Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
Study NCT00775918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline monohydrate 100mg tablets
Description: Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
Study NCT02765932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dummy Movements
Description: The placebo group will be asked to perform the same touch technique and count backwards from 50 while removing petals from a flower. Patients will also perform these techniques before rehab and sleep.
Study NCT02765932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosensory Therapy
Description: The research assistant will administer one of the several psychosensory touch techniques prior to surgery. This will involve the touching of upper arms, palms, and a visualization process. This will last no longer than 10 minutes. These techniques will also be performed by the patients prior to any rehab sessions and before going to sleep. The patients will be asked to perform these touch techniques with the eyes closed and imaging having no pain. The patients will also be asked to keep a record of all medications.
Study NCT02571452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia
Description: Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
Study NCT02571452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
Study NCT04396886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Bintrafusp alfa will be administered intravenously every 2 weeks
Study NCT01299493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems-level intervention to promote colon cancer screening
Description: Intervention practices will receive access to, and assistance in implementing, evidence-based strategies for increasing colorectal cancer screening rates.
Study NCT00841867 — intervention group
Intervention type: PROCEDURE
Intervention: All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.
Description: All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
Study NCT03660683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10mg PO QD
Study NCT03660683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10mg PO QD
Study NCT03660683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 5mg
Description: Saxagliptin 5 mg PO QD
Study NCT03660683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matching Placebo Tablets
Study NCT02543359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Models of PCIT
Description: Agency participants are trained in one of three training model strategies: Train the Trainer Model (TTT), Learning Collaborative (LC), or Web-Supported Self Study (SS).One third of participating agencies will be randomized to the Train the Trainer training model.One third of participating agencies will be randomized to the Learning Collaborative training model.One third of participating agencies will be randomized to the Web-Supported Self Study.
Study NCT02543359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Models of PCIT
Description: One-third of administrators are trained in the Learning Collaborative training model. One-third of administrators will be trained to usual treatment (none). One-third of administrators will be trained to usual treatment (none).
Study NCT02543359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT) Treatment
Description: Parent-Child Interaction Therapy (PCIT), a parent coaching evidence-based protocol is given to each family from clinicians and supervisors in each training model.
Study NCT00941603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900271 15mg
Description: oral tablets; SCH 900271 - 15 mg taken once daily for 8 weeks
Study NCT00941603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900271
Description: oral tablets; SCH 900271 10 mg taken once daily for 8 weeks
Study NCT00941603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900271
Description: oral tablets; SCH 900271- 5 mg taken once daily for 8 weeks
Study NCT00941603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900271
Description: oral tablets; SCH 900271- 2.5 mg taken once daily for 8 weeks
Study NCT00941603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900271
Description: oral tablets; SCH 900271- 1 mg taken once daily for 8 weeks
Study NCT00941603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
Study NCT03094689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Study NCT03094689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water immersion
Study NCT02513654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.
Study NCT00593372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spaced Retrieval Training
Description: Increasing time to remember important information.
Study NCT02488486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated postoperative sedation
Study NCT00415142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration (capsules)
Study NCT00415142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: oral administration (capsules)
Study NCT04538768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesh augmentation
Description: P4HB retromuscular mesh placement for prevention of lateral incisional hernia after stomal closure
Study NCT04538768 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Direct suture
Description: direct fascia suture
Study NCT03829449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVA576 (Coversin)
Description: The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).
Study NCT02843698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
Study NCT04590898 — intervention group
Intervention type: DEVICE
Intervention: Peri-device leakage closure after left atrial appendage occlusion
Description: Peri-device leakage closure after left atrial appendage occlusion
Study NCT03046147 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass
Description: Roux-en-Y gastric bypass surgery for morbid obesity
Study NCT03061773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physical training: The combined training program consisted of 12-week aerobic, resistive and flexibility exercises, with 3 sessions per week of aerobic and resistive training in the same session (supervised by physical exercise coaches) and 2 sessions per week of Flexibility training (unsupervised). As stretching sessions were interspersed with sessions of aerobic and weathered training in the daytime period.
Study NCT03061773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hospital treatment
Description: Conventional hospital treatment: The patients did not perform physical training
Study NCT01315366 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Euro D and Ci-CalD
Description: Ci-Cal D (1000mg/day) and vitamin D (500IU/day) daily, plus a supplement of vitamin D3 (20,000 IU/wk) for one year.
Study NCT01315366 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Euro D, Ci-CalD
Description: Ci-Cal D(1000mg/day) and vitamin D (500IU/day) Ci-CalD daily, plus a weekly placebo Euro D supplement for one year.
Study NCT02206724 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: STEREOTACTIC BODY RADIOTHERAPY to the prostate gland
Study NCT01330615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA
Description: The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
Study NCT01330615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
Study NCT04737915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy (In Vivo)
Description: Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a virtual environment.
Study NCT04737915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy (Virtual Reality)
Description: Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a real environment.
Study NCT04946422 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopy
Description: Discharge diagnosis of patients with sports injury-related injuries
Study NCT02451969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: investigational 23-valent PPV
Description: The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.
Study NCT02451969 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: control 23-valent PPV
Description: The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd.